Every week Cathie Wood, Ceo of Ark Invest, shares her weekly commentaries with investors about the performance of stocks and the strategies ARK Invest goes forward within transacting stocks of companies.
Intellia Therapeutics (NTLA)
50%
After publishing the first-ever clinical data confirming the safety and efficacy of in vivo genome editing, Intellia Therapeutics (NTLA), a pioneer in CRISPR gene editing, finished up 50% on Monday. The therapeutic candidate NTLA-2001 is promoted as a one-dose cure for hereditary ATTR amyloidosis (hATTR), a fatal illness characterized by excessive amyloid protein production. NTLA-2001 works by suppressing the TTR gene, which decreased amyloid accumulation by approximately 87 percent in this Phase 1 study. These findings match favorably to the current standard of treatment, which involves weekly injections throughout a patient's life to achieve an 80 percent amyloid reduction. These ground-breaking findings sparked investor interest in firms that deal with gene or base editing.
Verve Therapeutics (VERV)
21%
On Monday and Wednesday of this week, Beam Therapeutics (BEAM), a leader in base-editing medicine, gained 16 percent. Intellia's (NTLA) ground-breaking findings demonstrating the safety and efficacy of in vivo genome editing sparked investor interest in businesses like Beam, which are also involved in CRISPR genome editing or base-editing.
Editas Medicine (EDIT)
23%
On Wednesday, Editas Medicine (EDIT), a leading CRISPR-based gene-editing firm, saw its stock rise 23%. Intellia's (NTLA) ground-breaking findings demonstrating the safety and efficacy of in vivo genome editing sparked investor interest in CRISPR genome editing firms like Editas.
TuSimple (TSP)
15%
TuSimple (TSP), an autonomous transportation technology startup, gained over 16% on Monday despite no new information. As more firms in the area go public, investors may be learning more about the possibilities in autonomous trucking. Embark and, TuSimple's rivals recently went public via SPACs.
